Re­gen­eron’s Covid mAb as a pro­phy­lac­tic in­jec­tion: Re­duced risk of symp­to­matic in­fec­tion by 81%

Re­gen­eron’s mon­o­clon­al an­ti­body cock­tail for Covid-19 con­tin­ues to im­press, this time in a joint tri­al with NIH that found the nor­mal­ly in­fused treat­ment works as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER